Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
October 31, 2024 08:05 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference

Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture...
October 23, 2024 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer’s disease - Late-breaking presentation to be...
September 30, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
September 26, 2024 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s diseaseExtension to provide drug product (DP)...
September 25, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
September 03, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
August 13, 2024 07:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights

Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease Dosed the first subject in a Phase 1 study to support...
August 06, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
July 29, 2024 07:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...